3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specialized in the process development and GMP manufacturing of biologics, and the Swedish biotechnology company Intervacc AB, have secured the large-scale production of the vaccine against equine strangles called Strangvac. The technology transfer and scale-up of the manufacturing process with verification of reproducibility for Strangvac production has been completed. Intervacc intends to submit a registration ...